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In Brief
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INTRODUCTION
Different tumors accumulate genetic and epigenetic alterations conferring diverse molecular, cellular, and clinical features, a phenomenon known as intertumoral heterogeneity (Burrell et al., 2013) . Beyond their effects on tumor cells, these differences also affect the composition of the tumor microenvironment (TME). The TME comprises extracellular matrix and a combination of stromal and immune cells, all of which impact disease progression and clinical outcomes (Quail and Joyce, 2013) . How different tumor cells shape their TMEs, thereby determining response to therapy, remains a critical unsolved problem.
Therapeutic interventions targeting immune cells have led to marked improvements in clinical outcomes (Hodi et al., 2010; Larkin et al., 2015; Le et al., 2017; Topalian et al., 2012) . However, only a subset of patients responds to these therapies. Recent studies suggest that the degree of T cell infiltrationwhich might be regulated by tumor cell-intrinsic signaling pathways and gene regulatory networks-is a critical factor Ji et al., 2012; Kortlever et al., 2017; Peng et al., 2015; Spranger et al., 2015; Wang et al., 2016; Welte et al., 2016) .
Pancreatic ductal adenocarcinoma (PDA) is predicted to become the second leading cause of cancer death in the United States by 2025 (Rahib et al., 2014) . PDA exhibits substantial immunological heterogeneity, with tumors spanning the spectrum of T cell infiltration (Balli et (legend continued on next page) differences in T cell infiltration is poorly understood in PDA, where most tumors share the same oncogenic drivers. A detailed understanding of how distinct tumors regulate their respective immune landscapes has been constrained, at least in part, by a lack of appropriate experimental systems that faithfully recapitulate the heterogeneity of the TME. To better define the cellular and molecular basis of tumor immune variation, we employed an autochthonous mouse model of PDA (KPC) that recapitulates major features of the human disease, including mutated Kras and p53 (Hingorani et al., 2005; Rhim et al., 2012) . Immune populations were not uniform across tumors in KPC mice but instead varied widely with respect to the infiltration of lymphoid and myeloid cells, like their human counterparts. Based on this, we hypothesized that tumor-intrinsic factors other than mutant Kras or p53 are responsible for the natural variation in immune infiltration across PDA tumors. Here, using a new experimental system to model immune heterogeneity, we report that tumor cell-intrinsic factors shape the immune landscape in the surrounding TME, thereby determining sensitivity to immunotherapy.
RESULTS
Heterogeneity of the Immune TME Is a Tumor-CellIntrinsic Trait Examination of 24 treatment-naive resected PDAs revealed a wide distribution in the abundance of CD8 + and CD3 + T cells, with one subgroup categorized as T cell high (7/12) and one subgroup characterized as T cell low (5/12) ( Figures 1A and 1B) . Similarly, an examination of 24 primary tumors from KPC mice expressing the YFP lineage tag (KPCY) (Trp53 L/+ ) mice revealed variation in intratumoral T cells ( Figure 1C ). Thus, both human and murine PDA exhibits variation in the abundance of intratumoral CD8 + T cells. We hypothesized that transplanted tumor cells might retain the properties that drive this variation. To test this, we generated a library of congenic tumor cell clones from a cohort of fully backcrossed C57BL/6 KPCY (Trp53
LSL-R172H/+
) mice (Byrne and Vonderheide, 2016) and assessed immune infiltration following implantation ( Figure 1D , Figure S1A ). Despite sharing identical tumor-initiating alterations, the tumor cell clones elicited variation in CD8 + T cell infiltration ( Figure 1E ), with CD8 + T cell high (''T cell high'') PDA tumors exhibiting increased CD3 + T cells relative to CD8 + T cell low (''T cell low'') tumors ( Figure 1F ). Unsupervised clustering revealed two patterns of immune infiltration such that T cell high tumors were associated with increased dendritic cells and T cell low tumors were associated with increased myeloid cells ( Figure 1G ). We confirmed that the immune infiltrates elicited by each clone were robust and reproducible (Figure 1H) . Importantly, intratumoral T cells were located near tumor cells and not confined to the periphery of the tumor ( Figure 1I ). Thus, this tumor clone library establishes TMEs with substantial heterogeneity, allowing for interrogation across the spectrum of T cell infiltration.
Antigen load alone does not explain immune infiltration (Balli et al., 2017; Spranger et al., 2016) . We performed exome sequencing and neoepitope prediction of the clones (Evans et al., 2016; Rech et al., 2018) and found 0-5 somatic mutations and 0-3 predicted neoepitopes in both T cell high and low subgroups (Table S1 ). Expression of MHC class I was similar across tumor cell clones even after stimulation with interferon (Figure S1B) . Following orthotopic injection, clones gave rise to tumors with the expected pattern of immune infiltration ( Figures  1J and 1K) ; notably, subcutaneous and orthotopic tumors shared comparable histological and stromal features (Figure S1C) . Expected immune phenotypes were also preserved in two different animal facilities with distinct microbiomes ( Figure S1D ). These results suggest that tumor cell-intrinsic features other than mutational burden, site of injection, or host microbiome account for the observed differences in T cell infiltration.
T Cell Infiltration Influences the Progression of
Metastatic, but Not Primary, PDA We previously found that T cells do not alter the natural history of murine PDA (Evans et al., 2016) . Consistent with this finding, T cell depletion did not alter the growth of T cell high clones, indicating that T cells exert a limited effect on the primary tumor in the absence of additional stimulation ( Figure S1E ). By contrast, T cell low clones gave rise to metastases more efficiently than T cell high clones after tail vein injection (Figures 1L) or orthotopic implantation (Figures S1F-S1H). Metastatic burden was higher in NOD/SCID mice or after T cell depletion (Figures 1M and S1I) , indicating that the decreased metastatic capacity of T cell high clones is immune cell-dependent. These results suggest that T cell infiltration reduces the initiation and/or growth of metastatic lesions, consistent with results from other systems (Wculek and Malanchi, 2015) .
The Abundance of Intratumoral CD8 + T Cells Predicts
Response to Immunotherapy We have reported robust T cell responses against KPC-derived tumors with a combination of chemo-and immunotherapy, GAFCP (gemcitabine, G; nab-paclitaxel, A; anti-CD40 agonist, F; anti-CTLA-4, C; and anti-PD1-1, P) (Winograd et al., 2015) , which is now in clinical trials for PDA patients (NCT03214250, Table S1 and Figure S1 . Figures 2B and S2B) . Thus, response to immunotherapy is closely associated with T cell infiltration in our model. We found that 50% of mice bearing 2838c3 (T cell high) tumors experienced tumor regressions after treatment with checkpoint blockade alone, an effect that was enhanced with the addition of either agonistic CD40, combined chemotherapy, or both (Figures 2C and S2C) . Chemotherapy alone was ineffective, and gemcitabine sensitivity was unrelated to the degree of T cell infiltration ( Figures 2C and S2C and S2D ). Chemotherapy was not required for, nor did it impede, therapeutic benefit, as mice treated with FCP had similar tumor growth rates as those treated with GAFCP (Figures 2A and S2E ).
Although none of the mice bearing T cell low tumors cleared their tumors following therapy, we observed ''cures'' (survival > 6 months) in 20/26 mice bearing T cell high tumors treated with GAFCP, suggesting that durable T cell responses were generated. To interrogate the memory T cell response, we re-challenged animals that were cured of their tumors with either the same or different tumor cell clones. When mice cured of 2838c3 tumors with CD40 agonist-containing therapies were re-challenged with the same tumor clone, 100% rejected the newly implanted PDA cells ( Figure 2D , red curve), a protective effect that was lost upon T cell depletion ( Figure 2D , purple curve, and Figure S2F ). Interestingly, secondary responses were partially dampened when mice were cured with CP or GACP ( Figure 2D , green curve, and Figure S2F ), indicating that CD40 agonist improves anti-tumor immune memory.
Next, we challenged mice cured of two other T cell high tumors (6620c1 or 6499c4) after GAFCP therapy with 2838c3 cells. In both cases, there was marked growth suppression (Figures 2E and S2G) . To further explore this phenomenon, we challenged mice cured of primary 2838c3 tumors after GAFCP or GACP with the T cell low cell clone, 6419c5. Tumor growth was inhibited ( Figure 2F , blue curve), with tumor recurring in only a single mouse that did not receive agonistic CD40 ( Figure S2H ). These results indicate the existence of shared tumor antigens across T cell high and low tumor cell clones and suggest that T cell low tumors are susceptible to immune recognition once effective T cell responses are generated.
T Cell High Tumors Are Associated with an Increased Abundance of PD-1 + CD8 + T Cells
We hypothesized that T cell high tumors possess distinct cellular and molecular features relative to T cell low tumors. We first confirmed that tumor weight and total number of live cells and leukocytes were comparable between T cell low/high tumors (Figures S3A and S3B) . Investigation of CD4 + T cells revealed an increase in the proportion of both Treg and Th subsets (Figures 3A and S3C and S3D) , while CD4 + T cells exhibited only slightly more effector cytokine production ( Figure S3E ) in T cell high tumors.
We next interrogated molecular features of CD8 + T cells. The CD8/Treg ratio was skewed in favor of CD8 + T cells in T cell high versus low tumors ( Figure 3B ). Moreover, CD8 + T cells in T cell high tumors exhibited increased expression of CD44 and PD-1, signs of prior T cell activation ( Figures 3C-3D and S3F). CD8 + T cells in T cell high tumors also expressed higher levels of Nur77, a marker of T cell receptor (TCR) engagement, and T cell activation/inhibitory receptors including Lag3, CTLA-4, and Tim3, as compared to T cell low tumors ( Figure 3E ). The enhanced TCR activation status of CD8 + T cells in T cell high tumors is in keeping with the more antigen-experienced tumorreactive T cell populations described in other tumor types (Ahmadzadeh et al., 2009; Fourcade et al., 2010 ) and yet is only revealed in PDA when using these clonal tumor cell lines with dichotomous immune infiltration. There were no significant differences in cytokine production ( Figure 3F ) despite a slight increase in the absolute number of IFN-g + CD8 + T cells ( Figure S3G ). In addition, CD8 + cells in T cell high tumors were no more proliferative than their counterparts in T cell low tumors ( Figures 3G and S3H ). These findings suggest that despite their greater antigen experience, T cells from T cell high tumors fail to acquire robust effector function. Indeed, the proportion of CD8 + T cells expressing GzmB was reduced in T cell high versus low tumors ( Figure 3H ), underscoring the inability of T cells to achieve a fully functional status, even in the setting of a T cell high TME. Figure 3K ), resulting in tumor rejection and long-term survival ( Figure S3I ). By contrast, mice bearing 6422c5 tumors exhibited a delay in tumor growth but no regressions ( Figure 3L ) and only slightly improved overall survival after treatment ( Figure S3J ). Thus, consistent with observations from melanoma patients (Daud et al., 2016) , the abundance of pre-existing intratumoral PD-1 + CD8 + T cells, rather than CD8 + T cell infiltration alone, predicted sensitivity to immunotherapy in PDA.
(C) after treatment with GACP (n = 1) or GAFCP (n = 6) were challenged with the unrelated T cell low clone 6419c5 and survival was compared to naïve mice injected with 6419c5 (n = 5). Each symbol in the tumor volume curves represents the mean of a group of mice (n = 4-8), with error bars indicating SEM. Each bar in the waterfall plots represents a single mouse. Statistical differences were identified by linear mixed-effect modeling with Tukey's HSD post-test (A and B), or Kaplan-Meier with logrank test (C-F), with significance against control groups indicated next to group, or other comparisons indicated by brackets. In (C), the GA group was also at least ** versus all other treatment groups. See also Figure S2 .
Cross-Presenting Dendritic Cells and CXCR3 Are Necessary for CD8 + T Cell Infiltration Cross-presenting dendritic cells (DCs) play a critical role in presenting tumor antigens to CD8 + T cells (Roberts et al., 2016) .
Interrogation of the Cancer Genome Atlas (TCGA) dataset revealed that CD8A gene expression correlated with markers of cross-presenting DCs in PDA ( Figure 4A ). Likewise, we observed a correlation between cross-presenting DCs (CD103 + DCs) and (I) Tumor growth curves and waterfall plots at day 21 after the start of therapy in mice bearing T cell high clone 2838c3 tumors treated starting at day 12 with GAFCP (+/À aCXCR3) (n = 5-7 mice/group).
(legend continued on next page)
T cell infiltration into PDA tumors. To test this, we employed Batf3 À/À mice lacking CD103 + DCs (Hildner et al., 2008) . We observed an almost complete absence of CD8 + T cells in tumors arising in Batf3 À/À mice ( Figure S4A ) along with a loss of CD11c + DCs ( Figure S4B ). Moreover, only a small percentage of the rare tumor-infiltrating CD8 + T cells in Batf3 À/À mice expressed CD44
or PD-1 ( Figure 4C ). By contrast, other intratumoral immune cell subsets were minimally affected by the absence of CD103 + DCs ( Figure S4C) .
To examine T cell recruitment more directly, we adoptively transferred isogenically mismatched (Thy1. tration to the TME via the elaboration of CXCR3 ligands (Spranger et al., 2017) . Consistent with this notion, some T cell high tumor cells produced higher levels of CXCL9 and CXCL10 compared to T cell low tumor cells ( Figure 4F ). CXCR3 blockade reduced the total number of T cells in tumors ( Figure 4G ) and tumor draining lymph nodes (TDLNs) (Figure S4E ). However, CXCR3 blockade had no effect on the activation status of intratumoral CD8 + T cells ( Figure 4H ).
CXCR3 blockade also reduced the proportion of CD103 + DCs in tumors but not TDLNs ( Figure S4F ), consistent with prior studies (Desch et al., 2011) . These results suggest that activation of the effector PD-1 + CD8 + T cell subset can still occur despite CXCR3 blockade.
Our studies of the two T cell intermediate clones suggested that the proportion of PD-1 + CD8 + T cells as a percentage of total CD45 + cells correlates with response to immunotherapy.
We reasoned that CXCR3 blockade-which diminished total CD8 + T cells but left the PD-1 + subset intact-would only partially blunt the therapeutic efficacy of GAFCP therapy. In keeping with this hypothesis, 2838c3 tumor-bearing mice exhibited tumor regressions and long-term survival following GAFCP treatment despite CXCR3 blockade (Figures 4I and S4G) . These results indicate that therapeutic efficacy of the PD-1 + CD8 + T cell subset is preserved despite CXCR3 blockade.
T Cell Low Tumor Cell Clones Act Dominantly to Mobilize Myeloid Cells and Suppress T Cell Infiltration into the TME We next sought to determine the mechanism(s) by which different PDA clones establish either T cell high or low TMEs. Mice bearing T cell low tumors exhibited an expansion in total myeloid and gMDSC cells in peripheral blood and TDLNs (Figure 5A) , suggesting that these tumors promote systemic myeloid cell mobilization. To assess the impact of myeloid cell mobilization on tumor immune infiltration, we simultaneously injected individual mice with a T cell high tumor on one flank and a T cell low tumor on the contralateral flank ( Figure 5B ). Although T cell low tumors continued to exhibit abundant myeloid cell infiltration, the presence of a T cell low tumor had no effect on myeloid infiltration into a contralateral T cell high tumor ( Figure 5C , top). Likewise, T cell high tumors continued to exhibit robust infiltration of CD103 + DCs and CD8 + T cells despite bearing a T cell low tumor on the opposite flank ( Figure 5C , top and bottom). Thus, the systemic factors leading to increased myeloid populations in the blood and TDLNs of T cell low-bearing animals did not induce changes in the immune TME of anatomically separate tumors.
To investigate whether either tumor subtype exerts a dominant effect locally, we implanted a mixture of cells from T cell high and low clones in a single site ( Figure 5D ). The immune populations in these mixed tumors recapitulated the composition of T cell low tumors despite equal representation of the clones at the time of tissue harvest (Figures 5E and S4H) . This suggests that heterogeneity in immune infiltration is prescribed by the dominant local action of tumor cell-intrinsic factors that recruit gMDSCs to the TME, thereby subverting the anti-tumor T cell response.
Molecular Features, Including Differential Epigenetic Status and Gene Expression of Cxcl1, Distinguish T Cell Low and T Cell High Tumors
We hypothesized that our T cell high/low phenotypes might be the byproduct of somatic copy number alterations (SCNA), analysis of which revealed substantial genomic rearrangements in both T cell high and low clones with a trend toward increased SCNAs in T cell low clones ( Figures S5A and S5B) . For genomic loci, we previously identified as associated with a T cell low phenotype in human PDA (Balli et al., 2017) , we observed similar SCNA patterns in our murine PDA T cell low clones (e.g., enrichment for gains in Notch2 and c-Myc and loss of Cdkn2a/b) (Figures 6A and S5C) .
Because SCNAs can converge to activate (or repress) different molecular pathways, we undertook an integrative transcriptomic and epigenomic analysis of the T cell low and high clones. RNAseq analysis of bulk tumor samples ( Figure 6B ) revealed that, compared to T cell high tumors, T cell low tumors were enriched for signatures of E2F Targets, MYC targets, G2M checkpoints, and cell-cycle processes ( Figures 6C and S5D ) and had a reduced signature for T cell gene expression ( Figure S5E ). The differential enrichment of cell-cycle-related processes was also observed in RNA-seq analysis of sorted YFP + tumor cells (Figure S5F ) and was associated with a higher proliferation rate for T cell low clones ( Figure S5G ). Because our tumor clone mixing experiments suggested a role for secreted factors in local immune suppression, we identified three chemokines-Cxcl15, Ccl20, and Cxcl1-that were differentially expressed between T cell high/low tumors ( Figures Figure S4 . and 6D). To determine the tumor cell-intrinsic production of these factors, we analyzed RNA-seq data from sorted tumor cells and found that Cxcl1, which encodes a ligand for CXCR2, was the mostly differentially expressed chemokine . By contrast, two other ligands for CXCR2-Cxcl2 and Cxcl5-were not differentially expressed.
CXCR2 is required for myeloid cell infiltration into PDA Wang et al., 2016; Steele et al., 2016) , and we found that > 80% of gMDSCs expressed CXCR2 in both T cell high and low tumors ( Figure S5J ). To explore an epigenetic basis for the differential expression of Cxcl1, we performed ATAC-seq on sorted tumor cells and found that the Cxcl1 promoter region is more accessible in T cell low versus high tumor cells ( Figures  6G and 6H ). In addition, the Cxcl1 promoter was enriched for the H3K4me3 active histone mark in T cell low versus high tumor cells ( Figures 6I and S5K) . To further understand the transcriptional regulation of Cxcl1, we focused on MYC because: (1) MYC amplifications were enriched in T cell low clones (Figure 6A) ; (2) (legend continued on next page) E-box sites; (5) T cell low tumors had elevated expression of Pvt1 ( Figure 6D ), a long non-coding RNA that facilitates high MYC levels (Tseng et al., 2014) ; and (6) previous reports support a role for MYC in promoting an immunosuppressive TME (Casey et al., 2016; Kortlever et al., 2017; Natale et al., 2018) . c-Myc overexpression (Myc-OE) resulted in increased Cxcl1 expression in T cell high but not T cell low clones ( Figures 6J and S5L) . Conversely, treatment with bromodomain inhibitors, which reduce MYC protein levels (Delmore et al., 2011) , resulted in decreased Cxcl1 expression in T cell low clones (Figures 6K and S5M) but not in T cell high clones ( Figure S5N ), with comparable effects on cell survival and proliferation ( Figure S5O ). These results suggest that a combination of chromatin accessibility and MYC activity dictate the expression of Cxcl1. We and others have reported that PDA tumor-cell-derived GM-CSF promotes myeloid cell mobilization which suppresses anti-tumor immunity (Bayne et al., 2012; Pylayeva-Gupta et al., 2012) . However, Csf2 was not differentially expressed between T cell high versus low tumor cells ( Figure S6A ), suggesting that GM-CSF does not underlie these dichotomous immune phenotypes. Functionally, gMDSCs were similar in both tumor types except for a slight increase in the production of inducible nitric oxide synthase (iNOS) in T cell high tumors ( Figure S6B ) (Kumar et al., 2017) .
Ablation of CXCL1 in Tumor Cells Increases CD8 + T Cell Infiltration and Induces Responses to Immunotherapy
To determine whether tumor-cell-derived CXCL1 is a major driver of the immune TME, we generated T cell high clones overexpressing Cxcl1 (Cxcl1-OE) ( Figure S6C ), resulting in increased infiltration of myeloid cells and decreased infiltration of DCs and T cells ( Figures 7A and S6D) . Injection of T cell low clones into mice with a heterozygous or homozygous deletion of CXCR2 resulted in a decrease in intratumoral myeloid cells and gMDSCs ( Figure 7B , top) and a concomitant increase in CD103 + DCs and PD-1 + CD8 + T cells ( Figure 7B top and bottom). These results suggest that tumor cell-derived CXCL1 signals through CXCR2 + cells to establish a T cell low TME. To determine whether CXCL1 produced by tumor cells is required for the immunosuppressive phenotype, we generated Cxcl1 deficient (Cxcl1 À/À ) clones ( Figure S6E ) and found that CXCL1 ablation resulted in decreased infiltration by myeloid cells, especially gMDSCs ( Figure 7C ), and an increase in the infiltration of PD-1 + CD8 + T cells ( Figures 7C and 7D ). These data suggest that tumor cell-derived CXCL1 is necessary and sufficient to promote the recruitment of suppressive myeloid cells into PDA, thereby suppressing the infiltration of CD8 + T cells. To determine whether CXCL1 ablation renders T cell low tumors sensitive to immunotherapy, we treated animals bearing Cxcl1 mutant tumors with FCP. All (16/16) (Figure S6G) , indicative of a protective memory response. Thus, interfering with the CXCL1-CXCR2 axis-the major factor driving the formation of a non-T cell-inflamed TME and resistance to immunotherapy-converts the TME to a T cell-inflamed state capable of generating robust and protective anti-tumor responses.
Multiple Mechanisms Contribute to Immune Heterogeneity Because a single molecular mechanism is unlikely to explain all observed immune heterogeneity, we sought to identify other factors that might account for variation in the TME. Csf3 (G-CSF), which regulates myeloid cell infiltration into tumors (Welte et al., 2016) , was expressed at high levels by a single T cell low tumor clone, 6419c5 ( Figure S6H ). To determine whether this cytokine exerts effects on the TME, we generated Csf3-overexpressing (Csf3-OE) tumor cell lines ( Figure S6I ) and found Csf3 overexpression resulted in decreased T cells and increased gMDSCs, in 6499c4 tumors but not 2838c3 tumors ( Figure S6J ). Thus, increased tumor-cell-derived CSF3 is sufficient to convert a T cell high TME into a T cell low TME in a subset of tumors. Conversely, ablation of Csf3 in T cell low clone 6419c5 resulted in decreased gMDSC infiltration ( Figures S6K and S6L ) and sensitivity to FCP treatment ( Figures S6M and S6N) , including a partially protective memory response ( Figure S6O ). Importantly, Csf3 would not have been identified as a modulator of the TME using the genomic or transcriptomic approaches that enabled the identification of Cxcl1, as the expression of Csf3 and the chromatin accessibility of its promoter were similar when the tumor clones were examined as a group ( Figure S6P ). Collectively, these results indicate that CSF3 can contribute to the establishment of an immunosuppressive TME and confer resistance to immunotherapy in some-but not all-T cell low tumors, reinforcing the concept that the mechanisms of tumor immune heterogeneity are themselves heterogeneous, even within a genetically homogeneous cancer model.
DISCUSSION
Using a library of congenic tumor cell clones that recapitulate the immune heterogeneity of PDA, we found that each clone had reproducible genomic, epigenomic, and transcriptomic features that shaped its surrounding immune TME and determined sensitivity to immune interventions. Importantly, no single mechanism accounted for all intertumoral immune heterogeneity; instead, a variety of tumor cell-intrinsic events influenced the immune makeup of the TME.
Our focus on CXCL1 as a key tumor-cell-intrinsic regulator of immune phenotypes stemmed from mixing experiments 
(legend continued on next page)
showing that T cell low clones exerted a dominant effect, suggesting that local, soluble factor(s) promote non-T cell-inflamed TMEs. Unbiased RNA-seq and ATAC-seq nominated CXCL1 as a strong candidate, and functional experiments confirmed that tumor cell-derived CXCL1 acts as a molecular ''switch'' between the T cell high and low TME phenotype, with corresponding effects on sensitivity or resistance to therapy. Our finding that MYC acts in concert with epigenetic determinants to regulate Cxcl-1 expression complements recent work demonstrating that MYC suppresses antitumor immune responses (Casey et al., 2016; Kortlever et al., 2017; Natale et al., 2018) .
Other tumor-cell-intrinsic factors are likely to contribute to the establishment of a T cell low TME-each one playing a greater or lesser role in any given tumor. We found that CSF3 influences the makeup of the immune TME in a more limited subset of tumors compared to CXCL1. These observations underscore the conclusion that multiple mechanisms act in a combinatorial fashion to shape the TME, making it likely that the factors responsible for tumor immune heterogeneity are themselves heterogeneous. Additional investigation of the molecular programs underlying differential expression of CXCL1, CSF3, and other potential mediators of the T cell low TME-including our observation that T cell low tumors enriched cell-cycle signatures (Goel et al., 2017) -are likely to provide new therapeutic opportunities.
Previous studies have identified a correlation between CD8 T cell infiltration and response to immunotherapy in melanoma (Tumeh et al., 2014) . In PDA, a small subset of patients with MSI-high tumors exhibit T cell infiltration and sensitivity to immunotherapy (Le et al., 2017) . In our cohort of 12 PDA patients (none of whom are known to be MSI-high), we observed heterogeneity in the degree of T cell infiltration, in line with prior reports for PDA (Stromnes et al., 2017) . In several settings, the abundance of PD-1 + CD8 + T cells was more predictive of immunotherapy response than total CD8 + T cell infiltration alone. In our two in previously unresponsive T cell low clones. Thus, the presence of PD-1 + CD8 + T cells in the TME was strongly correlated with therapeutic response. By contrast, other features of CD8 + T cells-including cytotoxicity, proliferation, and cytokine production-were comparable between T cell high and low tumors. These results extend findings from previous efforts to identify biomarkers that predict the efficacy of immunotherapy in the clinical setting (Daud et al., 2016; Tumeh et al., 2014) (Roberts et al., 2016; Spranger et al., 2015; , but not via the CXCR3 pathway reported for melanoma (Spranger et al., 2017) . Thus, PDA has distinct trafficking and activation pathways for generating therapeutic CD8 T cell responses. GAFCP treatment resulted in an anti-tumor T cell memory against both T cell high and low clones, suggesting the presence of shared tumor antigens despite an inability to detect missensederived neoantigens following exome sequencing. These results contrast with previous reports in melanoma, where cross-protection against non-T cell-inflamed tumors was not observed (Spranger et al., 2017) . Thus, immunotherapy-refractory tumors such as PDA might utilize molecular mechanisms for immune suppression distinct from those observed in immunotherapysensitive malignancies such as melanoma that might render PDA more susceptible to T cell mediated killing once immunosuppression has been broken.
The library of clonal cell lines described herein represents a new experimental system for interrogating tumor heterogeneity. While we focused on the determinants of T cell infiltration and response to immunotherapy, we also observed marked differences in the metastatic competence of T cell high versus low clones, demonstrating the utility of this system for studying immune regulation of metastasis. Given the paucity of neo-epitopes in KPCY-derived tumors, a feature shared by human PDA Balli et al., 2017) , our tumor clone panel also represents a tool with which to interrogate the mechanisms behind the observation that overall survival in patients with PDA following resection correlates with intratumoral T cell infiltration (Balachandran et al., 2017) , a finding suggestive of immunemediated control of micrometastasis. Importantly, the reproducibility of the TME for each tumor clone and the spectrum of TMEs found across the clone library make this experimental platform well-suited for exploring other aspects of tumor heterogeneity and patient-specific optimization of therapy.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: regularly tested using MycoAlert Mycoplasma Detection Kit from Lonza. Three T cell low tumor cell clones (6419c5, 6694c2, and 6422c1), three T cell high tumor cell clones (2838c3, 6499c4, 6620c1), and two T cell intermediate clones (7160c5 and 6422c5) were used in further studies as indicated. All studies referring to n = 2 clones/group used clones 6419c5 and 6694c2 (in T cell low group) and 2838c3 and 6499c4 (in T cell high group).
Human Samples
Tissue samples were collected from 12 patients with treatment-naive pancreatic ductal adenocarcinoma (male, n = 6, average age at diagnosis = 63, age range 54 -77; female, n = 6, average age at diagnosis = 68, age range 57 -80). Patients had Stage IA to Stage IV disease, with the median (n = 6) patients having Stage IIA disease (n = 1 each with Stage IA, III, or IV disease, and n = 3 with Stage IIB disease). Tissues samples were collected at the time of surgical resection of the primary tumor and obtained under informed consent in accordance with the Declaration of Helsinki and acquired from the Oregon Health & Science University as part of the Oregon Pancreatic Tumor Registry and IRB protocol #3609.
METHOD DETAILS Patient Samples and Flow Cytometry
A subset of human pancreatic ductal adenocarcinoma samples previously evaluated for general leukocyte complexity by flow cytometry (Gunderson et al., 2016) were reassessed herein for CD8 T cell high and low sub-stratification in the gamma delta negative, natural killer cell negative subset of live, CD45 + CD3 + cells. Fresh pancreatic ductal adenocarcinoma samples were processed and stained for flow cytometry as previously described (Gunderson et al., 2016) . Briefly, samples were mechanically minced and enzymatically digested at 37 C in DMEM (GIBCO) supplemented with 2.0 mg/mL collagenase IV (GIBCO), 1.0 mg/mL hyaluronidase (Worthington), 0.1% soybean trypsin inhibitor, and 50U/mL DNase I (Roche) for 45 minutes with constant stirring. Single cell suspensions were filtered through a 100 mm filter and washed with FACS buffer (0.5% BSA/2.0 mM EDTA/PBS) prior to staining. Two million total cells were stained with antibodies as previously reported (Gunderson et al., 2016) . To segregate patient samples into CD8 T cell high and low groups, kmeans supervised clustering was used with n = 2 centers (kmeans function from R).
Analysis of TCGA Dataset
Data of the expression levels of CD8a and CD103 + DC genes in human PDA tumors were from The Cancer Genome Atlas (TCGA).
Samples included only those that are annotated as ''untreated, primary, pancreatic ductal adenocarcinoma'' (PAAD, n = 134), the gene expression profiles of these samples were downloaded and processed for transcripts per kilobase million (Tpm) as previously described (Balli et al., 2017) . Gene expression of CD8A and markers for CD103 + DCs, including BATF3, IRF8, THBD, CLEC9A, and XCR1 (Spranger et al., 2017) , was analyzed using Pearson correlation analysis and reported R 2 values and p values from the analysis.
All correlation analysis resulted in p value < 0.0001, identified as significant.
Analysis of Somatic Copy Number Alterations (SCNA) by Sparse Sequencing
Somatic copy number alterations were discerned via sparse shot-gun sequencing of multiplexed Illumina sequencing libraries generated from DNA purified from low passage cell lines as described previously (Baslan et al., 2015) . In brief, 1 ug of purified genomic DNA was sonicated, end-repaired and A-tailed. This was followed by Illumina dual-index adaptor ligation and library enrichment/amplification. Libraries were quantified, pooled and sequenced on an Illumina HiSeq2500 machine (single end 76 base pairs) in multiplex fashion with a mean of 2.5 million reads per sample, sufficient to confidently ascertain SCNAs at a resolution of 60kb bins. Sequence data was analyzed as previously described (Baslan et al., 2012) . In brief, sequencing reads were mapped to mouse genome reference mm9 with uniquely mapped reads counted in genomic bins adjusted for map-ability. Read counts were subsequently normalized for GC content and segmentation performed using Circular Binary Segmentation (CBS). Copy number segments found above the mean of the genome were inferred as gains while segments found below the mean were inferred as losses. Loci were selected according to a previously published analysis of T cell infiltration and the occurrence of somatic copy number alterations in TCGA datasets (Balli et al., 2017) .
Analysis of Whole Exome Sequencing, Mutation Analysis, and Neo-Epitope Prediction Whole exome sequencing was performed using the SureSelect Mouse All Exon kit (Agilent, . Libraries were sequenced on a Nextseq500 platform to a depth of 100X for tumor cell lines and 50x for normal germline tissue (150 bp PE reads). FASTQ reads passing QC were aligned to the mm10 reference genome using NextGenMap (Sedlazeck et al., 2013) (version 0.5.0) . Duplicated reads were marked with Picard tools (version 2.17.4) and base recalibration performed with GATK (version 4.0). Somatic variants were identified using Mutect2 (GATK version 4.0) and Strelka2 (version 2.7.0) (Kim et al., 2017) annotated with SnpEff (version 4.3T). Variants were intersected and only variants called by both Mutect2 and Strelka2 were kept (Callari et al., 2017) . Neoepitope prediction and MHC binding-affinity were calculated using the antigen.garnish R package (Rech et al., 2018) . For MHC class I predictions, established median half-maximum inhibitory concentrations (IC 50 ) of < 5,000nM or < 50nM were used to classify peptides as potential MHC binders or as CDNs, respectively. These cutoffs correspond to experimentally confirmed peptide-MHC binding and immunogenic CDN thresholds, respectively (Fritsch et al., 2014; Paul et al., 2013) .
Analysis of RNA-Seq, Differential Gene Expression, GSEA Molecular Signature Analysis RNA was isolated from bulk tumor samples or sorted YFP+ tumor cells from subcutaneously implanted tumors using the QIAGEN RNeasy Plus Micro Kit per manufacturer's instructions. RNA purity and integrity were verified on an Agilent 2100 Bioanalyzer prior to library construction followed by paired-end 75bp sequencing on an Illumina Nextseq 550 high-throughput sequencer. RNA-seq analysis was performed using bcbio-nextgen (https://github.com/chapmanb/bcbio-nextgen). Fastq files were checked for quality using FastQC and qualimap. Alignment was performed using the STAR aligner under default settings with the mm10 reference genome. Raw counts of gene transcripts were obtained from the resulting bam files using featureCounts (Liao et al., 2014) . The raw count matrix was subsequently imported into R-studio (R version 3.3.3) and used as input for DESeq2 following the vignette of the package (Love et al., 2014) for normalization and differential gene expression analysis. Salmon/Sailfish was used in parallel to normalize and quantitate gene expression in transcripts per million (TPM) through quasi-alignment. Differentially expressed genes from the DESeq2 analysis were used as input for GSEA MSigDB geneset enrichment analysis (http://software.broadinstitute.org/ gsea/msigdb). To generate the volcano plots, we used the ggplot2 R package. Briefly, DESeq2 differential expression data were generated as described for T cell low versus high bulk tumor and sorted YFP+ cells. P values were adjusted for multiple comparisons by Benjamini-hochberg correction implemented in the base-r package. Log base 2-fold change from T cell low compared to high tumors of each gene was plotted on the x axis and the negative log base 10 of adjusted pvalues was plotted on the Y. Genes of interest and those with an adjusted p value less than 0.1 and log2 fold change > 1.5 were annotated with ensembl gene symbols.
Analysis of ATAC-Seq ATAC-seq samples were prepared by sorting 50,000 YFP + tumor cells from subcutaneously implanted tumors derived from each tumor cell clones. The libraries were prepared as previously published (Pauken et al., 2016) . The libraries were verified on an Agilent 2100 Bioanalyzer followed by paired-end sequencing on an Illumina Hiseq 4000 high-throughput sequencer. Mouse (GRCm38, May 23 2014) reference genomes were downloaded from UCSC repository and mouse gene models were derived from Gencode vM11. Quality assessment of raw reads was achieved with FastQC and contaminants were removed using Trimgalore with parameters '-q 15-length 20-stringency 5 0 . Bulk ATAC-seq samples were mapped to the reference genomes using BWA (Li and Durbin, 2010) . Reads aligned to the mitochondrial genome as well as reads mapping to multiple genomic loci were discarded from downstream analyses. Additionally, Picard minimized the PCR amplification bias in ATAC-seq samples. ATAC-seq samples were filtered using previously described quality standard (Buenrostro et al., 2013) . In brief, libraries containing less than 10,000 fragments or libraries with less than 15% of their fragments falling in open chromatin were also removed from subsequent analyses. Macs2 with '-p 1e-7-nolambda-nomodel' was applied to each ATAC-seq replicate separately to identify accessible chromatin. An IDR threshold of 5e-2 was used, following the pipeline described above, to identify accessible chromatin for every ATAC-seq sample. Visualization was achieved by uploading the reads-per-million-aligned-read-normalized bigwig files to the University of California at Santa Cruz (UCSC) Genome Browser with smoothing window 5. Reads were counted for each region for each sample using featureCounts (Liao et al., 2014) . The resulting count table was analyzed for regions with differential accessibility between T cell high and T cell low samples using DESeq2 (Love et al., 2014) .
Implantation of Tumor Cell Clones
Cultured tumor cells were dissociated into single cells with 0.25% trypsin (GIBCO), washed with serum-free Dulbecco's Modified Eagle's medium (DMEM) twice, and counted in preparation for subcutaneous (s.c) or orthotopic implantation. 1.5x10 5 to 3.0x10 5 tumor cells were implanted s.c. and 3.0x10 4 to 5.0x10 4 tumor cells were implanted orthotopically into 6-8week age C57BL/6 mice.
Tumors were harvested 3-4 weeks following implantation. For mixing experiments, 6419c5 T cell low clone was transduced with a LentiV2 CRISPR vector harboring YFP sgRNA and mCherry expression cassette. We confirmed the lack of YFP expression and the existence of expression of mCherry visually using fluorescence microscope. Based on previous experiments ( Figure S5G ) we mixed 1.5x10 5 6419c5-mCherry cells with 3.0x10 5 2838c3 cells together before implantation.
Flow Cytometry of Murine Tumor Samples
Tumors were minced and incubated for 45 minutes in 1mg/mL collagenase IV in DMEM at 37 C and filtered through a 70 mM cell strainer for the preparation of single cell suspension. Cell surface molecules were assessed by incubating single cell suspensions from tissues with primary fluorophore-conjugated antibodies on ice for 45 minutes in PBS with 5% FBS and DNase I (Sigma). For intracellular cytokine quantification, single cell suspensions were incubated for 4hours at 37 C with PMA/ionomycin (Sigma) and Brefeldin A (Sigma). Intracellular staining was performed using the fixation/permeabilization (eBiosciences) according to the manufacturer's instructions. Antibodies used in flow analysis are described in the Supplementary information. Flow cytometric analysis was performed on a LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo software (Treestar). 
H&E Staining and Immunofluorescence Staining
Tissues were fixed in Zn-formalin for 24 hours and embedded in paraffin for histological analysis and immunofluorescence staining. Sections were deparaffinized, rehydrated and prepared by antigen retrieval for 5 minutes each, and then blocked in 5% donkey serum for 1 hour at room temperature, incubated with primary antibodies for overnight at 4 C, washed, incubated with secondary antibodies for 1 hour at room temperature, washed and mounted. Primary antibodies used include goat anti-GFP (Abcam), rabbit anti-CD3 (Abcam), rat anti-EMCN (Santa Cruz), rabbit anti-b-catenin (Cell signaling), rabbit anti-Collagen type I (Abcam), rabbit anti-PDGF Receptor b (Abcam), rabbit anti-alpha-SMA (Abcam), goat anti-SPARC (R&D). Slides were imaged and visualized using an Olympus IX71 inverted multicolor fluorescent microscope and a DP71 camera.
In Vitro Treatment with IFN-b and IFN-g for MHC I Expression Analysis Cells were treated with 100ng/mL of IFN-g (Peprotech) and/or 1,000 units/mL IFN-b (PBL Assay Science) for 24 hours. Single cell suspensions were stained with MHC I mAb (Biolegend) on ice for 30 minutes and washed twice with PBS with 5% FBS for flow analysis.
Depletion of CD8+ and/or CD4+ T Cells In Vivo CD4 + and CD8 + T cells were depleted using 200 mg of clone GK1.5 and clone 2.43, respectively, injected i.p. on 3 days before tumor implantation and repeated every 3 days for the duration of the experiment; other mice received isotype control (clone LTF-2, BioXcell). CD4 + and CD8 + T cell depletion was confirmed by flow analysis of peripheral blood.
Immune Infiltration Segregation and Clustering Analyses
To segregate mouse tumor clones into CD8 T cell high and low groups, kmeans supervised clustering was used with n = 2 centers (kmeans function from R). This grouping analysis was supported by performing unsupervised hierarchical clustering on two dimensions using hclust function with 'complete' method from R. The heatmap was drawn using ggplots package from R, and 2 classes of tumor cell clones were distinguished by their immune cell markers' abundance.
Lung Metastatic Colonization Assay 1.0x10 5 tumor cells were injected via tail vein into C57BL/6 or NOD/SCID mice. After 14 or 21 days, lungs were harvested and weighed, and metastatic burden was evaluated using a fluorescent stereomicroscope to count gross lesions.
Subcutaneous Tumor Growth, Regression, and Animal Survival Assessment Tumor sizes were measured every 2-3 days for tumor growth assessment experiments. Tumor length and width were measured with calipers and tumor volumes were then calculated as length*width 2 /2. Tumor volumes of 500 mm 3 were used as an endpoint for survival analysis. Tumor regressions and waterfall plots were calculated using the initial tumor size at the start of treatment to tumor size 21 days later. For the secondary tumor challenges, tumor cell clones were implanted into mice cured of primary tumors for > 90 days.
Assessment of IC50 Value for Gemcitabine Of Tumor Cell Clones 2.5x10 3 cells were seeded in each well of 96-well plates and treated with gemcitabine one day following cell seeding. Cell viability were assessed three days after gemcitabine treatment using Cell Cytotoxicity Assay Kit (Colorimetric). IC50 value were determined using Graphpad Prism6.
In Vivo Reagents For chemotherapy, gemcitabine (Hospira) and Nab-paclitaxel (Abraxane, Celgene) were purchased from the Hospital of the University of Pennsylvania Pharmacy. Gemcitabine (G) was procured as pharmaceutical grade suspension at 38mg/mL, diluted to 12mg/mL in PBS and administered at 120mg/kg via intraperitoneal (i.p.). injection. Abraxane (A) was purchased as a pharmaceutical grade powder resuspended at 12mg/mL in PBS for i.p. injection at dose of 120mg/kg. Vehicle control mice received the equivalent molar dose of human albumin (huAlb; Sigma) to nab-paclitaxel i.p. Chemotherapy was injected at day 9-14, when tumor size was 3-5mm. For anti-CD40 agonist treatment, mice were injected i.p. with 100 mg of either agonist CD40 rat anti-mouse IgG2a mAb (clone FGK45, endotoxin-free), or the isotype control IgG2a mAb (clone 2A3, BioXcell), and administered 48hrs after chemotherapy administration. For checkpoint blockade treatment, mice were injected i.p. with 200 mg of PD-1 (clone RMP 1-14, BioXcell) and 200 mg CTLA4 (clone 9H10, BioXcell), or the isotype control IgG2a mAb (clone 2A3, BioXcell), and starting day 9-14 (therapy start time point) and continued 7 times and 3 time respectively. CXCR3 blockade was performed using clone CXCR3-173 (500 mg) starting three days before tumors were implanted and repeated every two days for the duration of the experiment. All antibodies were purchased from BioXCell (Lebanon, NH).
analysis of tumor growth and survival curves, which were performed using linear mixed-effects model with Tukey's HSD post-test using the lme4 and the survival package in R. Error bars show standard deviation (SD) or standard error of the mean (SEM) shown as indicated in legend, and p < 0.05 was considered statistically significant. * indicates p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 unless otherwise indicated. ns denotes not significant, ND indicated not detected, and NA indicates not analyzed.
DATA AND SOFTWARE AVAILABILITY

Data Resources
The RNA-seq and ATAC-seq data has been deposited at the GEO: GSE109972 (https://www.ncbi.nlm.nih.gov/geo/). The genome sequencing data has been deposited at the SRA: SRP132299 (https://www.ncbi.nlm.nih.gov/sra). Software PRISM software was used for the statistical analysis and data visualization (http://www.graphpad.com). The R language and environment for statistical computing and graphics (https://www.r-project.org) was utilized in this study for the statistical and bioinformatics analysis of RNA-seq, ATAC-seq, and genome-seq data. The R packages used for the analysis described in the method section were obtained from the Bioconductor (https://www.bioconductor.org) and CRAN (https://cran.r-project.org/web/ packages/).
